TargED announces first patient successfully dosed in study of TGD001 in immune-mediated thrombotic thrombocytopenic purpura
Venture Challenge alumnus TargED Biopharmaceuticals announced that the first patient has been dosed in a Phase 1/2 proof-of-concept clinical study evaluating TGD001 as a potential treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) and other thrombotic microangiopathies (TMAs). Initial data from the study are expected in 2027.
ITTP is a serious and life-threating condition characterized by microvascular thrombosis and end-organ damage due to autoantibodies against the ADAMTS13 enzyme. It is a rare disease that affects thousands of patients each year and despite advances in care, there are no approved drugs capable of degrading the pre-existing thrombi. As such, many patients suffer neurological complications and long-term organ damage.
“This is an important milestone and we are tremendously grateful to the study physicians, patients and teams who have made this happen.” - Kristof Vercruysse, CEO of TargED
TGD001, TargED’s lead program, is a targeted thrombolytic designed to effectively dissolve blood clots in a broad range of thrombotic indications. By degrading both von Willebrand factor (VWF) and fibrin, TGD001 has the potential to dissolve clots of varying composition and location. TargED has reported positive first in-human results, demonstrating a favorable safety and tolerability profile, with no spontaneous bleeding events observed. In addition, TGD001 has showed potent thrombolytic activity, including rapid plasminogen activation and increased fibrin degradation products (D-dimer).
“Based on the very encouraging results of our healthy volunteer trial and our ongoing study in acute ischemic stroke, we are delighted to now be advancing TGD001 for evaluation in patients with iTTP. We believe that TGD001 has the potential to redefine the standard of care for iTTP patients by resolving their clot burden and consequently improving outcomes, providing patients and physicians with a new therapeutic option that can reduce severe disability and save lives.” - Josefin-Beate Holz, MD, Chief Medical Officer at TargED
The aim of the current study is to establish tolerated doses of TGD001 that show signs of pharmacological activity during the dose escalation part, and then to further establish TGD001’s safety profile and early clinical activity in the Phase 2 part, which will also include patients with other types of TMA. The trial expects to enroll up to 70 patients (EU Clinical Trial Identifier: 2025-523802-34-00 and Clinical Trials.gov: NCT07459114). The multi-regional study is currently open for enrollment at sites in Europe and the US, with additional regions and sites in activation.
Source (adapted from): TargED